NCT02965040View on ClinicalTrials.gov

A Phase 1 Study of Roxadustat in Subjects With Different Degrees of Renal Function

PHASE1CompletedINTERVENTIONAL

Enrollment

34

Participants

Timeline

Start Date

December 12, 2016

Primary Completion Date

December 4, 2017

Study Completion Date

December 11, 2017

Conditions

Normal Renal FunctionImpaired Renal Function

Interventions

DRUG

Roxadustat

Oral

Trial Locations (2)

81241

Site DE49001, München

L7 8XP

Site GB44001, Liverpool

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

FibroGen

INDUSTRY

lead

Astellas Pharma Europe B.V.

INDUSTRY